Get the Stockscreener App
1.58
9.72%
0.14
After Hours:
1.47
-0.11
-6.96%
Cocrystal Pharma Inc stock is traded at $1.58, with a volume of 82.78M.
It is up +9.72% in the last 24 hours and down -4.24% over the past month.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
See More
Previous Close:
$1.44
Open:
$2.45
24h Volume:
82.78M
Relative Volume:
62.51
Market Cap:
$16.21M
Revenue:
-
Net Income/Loss:
$-17.93M
P/E Ratio:
-0.8927
EPS:
-1.77
Net Cash Flow:
$-14.28M
1W Performance:
+7.12%
1M Performance:
-4.24%
6M Performance:
-3.36%
1Y Performance:
-5.95%
1-Day Range:
$1.54
$2.67
1-Week Range:
$1.42
$2.67
52-Week Range:
$1.12
$3.26
Cocrystal Pharma Inc Stock (COCP) Company Profile
Name
Cocrystal Pharma Inc
Sector
Industry
Phone
(786) 459-1831
Address
19805 N. CREEK PARKWAY, BOTHELL, WA
Compare COCP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COCP
Cocrystal Pharma Inc
|
1.58 | 14.98M | 0 | -17.93M | -14.28M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-08-20 | Initiated | H.C. Wainwright | Buy |
Cocrystal Pharma Inc Stock (COCP) Latest News
Cocrystal’s norovirus drug CDI-988 advances to phase 1b study By Investing.com - Investing.com Australia
Analyzing drawdowns of Cocrystal Pharma Inc. with statistical toolsJuly 2025 PreEarnings & Verified Swing Trading Watchlists - Newser
Is Cocrystal Pharma Inc. still worth holding after the dip2025 Top Gainers & Free High Return Stock Watch Alerts - Newser
Cocrystal Pharma Announces Stock Offering and Warrant Placement - TipRanks
Is Cocrystal Pharma Inc. stock ready for a breakout2025 Investor Takeaways & AI Powered Market Entry Ideas - Newser
Cocrystal Pharma Advances CDI-988 to Phase 1b Study - TipRanks
What candlestick patterns are forming on Cocrystal Pharma Inc.Weekly Trade Analysis & Reliable Intraday Trade Alerts - Newser
Cocrystal Pharma’s Significant Breakthrough - timothysykes.com
Published on: 2025-09-12 14:40:29 - Newser
Measuring Cocrystal Pharma Inc.’s beta against major indicesOil Prices & Short-Term High Return Ideas - Newser
Cocrystal Pharma Inc. stock retracement – recovery analysisForecast Cut & AI Forecast Swing Trade Picks - Newser
Cocrystal Pharma raises $4.7 million in registered direct offering - Investing.com
Analyzing Cocrystal Pharma Inc. with multi timeframe chartsJuly 2025 Breakouts & Detailed Earnings Play Strategies - Newser
Cocrystal Pharma (COCP) Announces $4.7M Direct Offering and Warrant Issuance - GuruFocus
Cocrystal Pharma announces up to $13 mln direct offering priced at-market under Nasdaq rules - MarketScreener
Cocrystal Pharma’s Momentum: Rise or Fall? - StocksToTrade
Tools to assess Cocrystal Pharma Inc.’s risk profileProduct Launch & Fast Entry Momentum Alerts - Newser
Cocrystal Pharma Skyrockets as Norovirus Antiviral CDI-988 Takes Center Stage - RagingBull
Cocrystal Pharma announces up to $13M registered direct offering - TipRanks
Cocrystal Pharma, Inc. Announces Up To $13 Million - GlobeNewswire
$13 Million Capital Raise: Cocrystal Pharma Secures $4.7M Upfront Plus $8.3M in Warrant Potential - Stock Titan
COCP’s Norovirus Breakthrough: Opportunity or Risk? - timothysykes.com
Cocrystal’s norovirus drug CDI-988 advances to phase 1b study - Investing.com
Cocrystal Pharma showcases CDI-988, antiviral for norovirus infection - TipRanks
Cocrystal Pharma Presents Clinical Progress of CDI-988, a Novel Antiviral for Norovirus, at 9th International Calicivirus Conference - Quiver Quantitative
Cocrystal Pharma Showcases CDI-988, the First Oral - GlobeNewswire
First-Ever Oral Drug for $60B Norovirus Market: Cocrystal's CDI-988 Shows Promise in Phase 1 Safety Study - Stock Titan
How sentiment analysis helps forecast Cocrystal Pharma Inc.Bear Alert & Risk Managed Investment Strategies - Newser
Has Cocrystal Pharma Inc. found a price floorJobs Report & Precise Swing Trade Alerts - Newser
What momentum shifts mean for Cocrystal Pharma Inc.2025 Major Catalysts & Consistent Profit Alerts - Newser
Understanding Cocrystal Pharma Inc.’s price movementEarnings Trend Report & Trade Opportunity Analysis Reports - Newser
What technical models suggest about Cocrystal Pharma Inc.’s comebackChart Signals & Daily Momentum Trading Reports - Newser
Applying Wyckoff theory to Cocrystal Pharma Inc. stock2025 Analyst Calls & Weekly Watchlist of Top Performers - Newser
Is Cocrystal Pharma Inc. forming a bottoming baseJuly 2025 PreEarnings & Stepwise Trade Execution Plans - Newser
Long term hold vs stop loss in Cocrystal Pharma Inc.Trade Volume Report & Risk Controlled Daily Trade Plans - Newser
Market reaction to Cocrystal Pharma Inc.’s recent newsBear Alert & Momentum Based Trading Signals - Newser
applying wyckoff theory to cocrystal pharma inc. stockWeekly Market Outlook & Target Return Focused Stock Picks - Newser
Will Cocrystal Pharma Inc. outperform the marketJuly 2025 Macro Moves & Community Supported Trade Ideas - Newser
Cocrystal Pharma’s norovirus antiviral study receives FDA clearance - Clinical Trials Arena
Cocrystal Pharma Inc. stock trendline breakdownJuly 2025 Selloffs & Free Fast Gain Swing Trade Alerts - Newser
Price momentum metrics for Cocrystal Pharma Inc. explainedMarket Trend Review & AI Driven Stock Reports - Newser
Is Cocrystal Pharma Inc. stock poised for growthGDP Growth & Safe Capital Growth Tips - Newser
Why Cocrystal Pharma Inc. is moving todayJuly 2025 Highlights & Smart Swing Trading Alerts - Newser
Is Cocrystal Pharma Inc. benefiting from innovation trends2025 Historical Comparison & Free Fast Entry Momentum Trade Alerts - 뉴스영
Cocrystal Pharma Inc Stock (COCP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):